FDA Rejects Lead Gene Therapy BLA Pathway, Recommends New Trial; Other Programs Face Setbacks

summarizeSummary

uniQure N.V. announced that the FDA rejected its BLA pathway for lead candidate AMT-130, requiring a new trial, while two other gene therapy programs (AMT-191 and AMT-162) faced clinical trial pauses due to safety concerns. A class action lawsuit has been filed, and insiders adopted plans to sell shares.

check_boxKey Events

• FDA Rejects BLA Pathway for Lead Candidate AMT-130

  The FDA stated that Phase I/II data for AMT-130 (Huntington's disease) are insufficient for a marketing application and strongly recommended a new, prospective, randomized, double-blind, sham surgery-controlled study, significantly delaying potential approval.

• Clinical Trial Pauses for AMT-191 and AMT-162

  Enrollment for the AMT-162 SOD1-ALS trial was voluntarily paused due to a dose-limiting toxicity, and dosing in mid- and high-dose cohorts for the AMT-191 Fabry disease trial was paused due to asymptomatic Grade 3 liver enzyme elevations.

• Class Action Lawsuit Filed

  A class action complaint was filed on February 10, 2026, alleging false and misleading statements regarding the AMT-130 Phase I/II study and the timing of its potential BLA filing.

• Strong Cash Position Despite Dilutive Offerings

  The company reported $622.5 million in cash and equivalents as of December 31, 2025, providing a runway into the second half of 2029, largely due to $404.2 million raised through dilutive public offerings in 2025.

auto_awesomeAnalysis

uniQure N.V. faces a significant setback as the FDA has deemed its Phase I/II data for AMT-130, its lead Huntington's disease gene therapy candidate, insufficient to support a Biologics License Application (BLA) submission. The FDA strongly recommended a new, prospective, randomized, double-blind, sham surgery-controlled study, indicating substantial delays and increased development costs for the program. This news, disclosed in the 10-K and concurrently in an 8-K, fundamentally alters the commercialization timeline and investment thesis for AMT-130, despite earlier positive topline data and Breakthrough Therapy designation. Further compounding the challenges, the company voluntarily paused enrollment for its AMT-162 SOD1-ALS trial due to a dose-limiting toxicity and paused dosing in mid- and high-dose cohorts for its AMT-191 Fabry disease trial due to liver enzyme elevations. A class action lawsuit has also been filed, alleging false and misleading statements regarding AMT-130's study and BLA timing. While the company maintains a strong cash position of $622.5 million, sufficient to fund operations into the second half of 2029, this runway was significantly bolstered by dilutive public offerings in 2025 totaling $404.2 million. The substantial drop in stock price since the September 2025 offering ($47.50 to $8.65) highlights the market's negative reaction to these developments. Additionally, the CEO, Chief Legal Officer, and a Non-executive Director adopted Rule 10b5-1 plans in October 2025 to sell shares, signaling a lack of insider conviction ahead of these critical disclosures.